H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on CytomX Therapeutics (CTMX) to $10 from $5 and keeps a Buy rating on the shares. The firm says “strong” CX-2051 trial demand and expansion of enrollment to 100 patients should provide a stronger signal for an approval path.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics price target raised to $6.50 from $5 at Piper Sandler
- CytomX Therapeutics Earnings Call Highlights Clinical Progress
- CytomX Therapeutics Reports Q3 2025 Financial Results
- CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)
- CytomX Therapeutics Advances CX-2051 Study in Solid Tumors